Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from...

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Tumor hypoxia is a hallmark of cancer, contributing to treatment resistance and metastasis.
• Hypoxia-selective prodrugs offer targeted cancer therapy by activating prodrugs in hypoxic tumor regions.
• Small-molecule tubulin polymerization inhibitors act as antiproliferative agents and vascular disrupting agents (VDAs).

Purpose of the Study:

• To design and synthesize novel bioreductively activatable prodrug conjugates (BAPCs) for hypoxia-selective cancer therapy.
• To evaluate the efficacy of BAPCs as both cytotoxic agents and VDAs in preclinical cancer models.
• To identify lead compounds with potent anti-cancer activity under hypoxic conditions.

Main Methods:

• Structure-activity relationship studies identified lead molecules targeting the colchicine site on tubulin.
• Synthesis of BAPCs using ether-linked heteroaromatic hypoxia-selective triggers with a nitro group.
• In vitro evaluation of BAPCs against A549 lung carcinoma cells under normoxic and anoxic conditions.
• In vivo assessment of a representative BAPC (KGP291) in nude mice with orthotopic 4T1 breast tumors.

Main Results:

• Several synthesized BAPCs exhibited positive hypoxia cytotoxicity ratios, indicating selective activity under anoxia.
• Lead compounds like OXi6196, KGP05, KGP18, and OXi8006 showed promise.
• Preliminary in vivo studies with KGP291 demonstrated significant vascular shutdown in tumors.

Conclusions:

• The developed BAPCs represent a promising strategy for targeting tumor hypoxia.
• KGP291 shows potential as a VDA, effectively disrupting tumor vasculature.
• Further investigation of these hypoxia-targeted agents is warranted for cancer treatment.